Still in the Red
Posted by Osagie K. Obasogie May 4, 2007
Biopolitical Times
Nitromed - makers of BiDil, the first FDA approved race based medicine - released its first quarter results for 2007, and it looks like their boat is still slowly sinking. While sales improved to $3.6 million (up $1.3 million compared to the same time last year), they spent $13 million in operating costs, making their net loss for the quarter $10.1 million. BiDil is still NitroMed's only product on the market; Keith Knight's comic below might partially explain the drug's sluggish sales.
(Click on image for better resolution)
(Click on image for better resolution)